medwireNews: Sodium-glucose cotransporter (SGLT)2 inhibitors, a type of diabetes drug, are associated with a lower risk for gout than dipeptidyl peptidase (DPP)-4 inhibitors, research suggests.
Discussing the link between gout and type 2 diabetes, Bernard Cheung (University of Hong Kong, China) and colleagues say that the two conditions are associated “under the umbrella of metabolic syndrome,” with gout linked to an elevated risk for hypertension, obesity, and cardiovascular disease. Moreover, “hyperuricaemia is involved in the development of insulin resistance [and] both conditions express pathological activation of interleukin-1β,” they add.
The team evaluated the risk for new-onset gout among 43,201 people with type 2 diabetes treated with SGLT2 inhibitors (n=16,144) or DPP-4 inhibitors (n=27,057) in Hong Kong between 2015 and 2020, of whom 3.84% developed gout during a median follow-up of 5.6 years.
After propensity score matching, the 16,144 people treated with SGLT2 inhibitors had a significantly lower risk for developing gout than the same number of matched individuals on DPP-4 inhibitors, with a hazard ratio (HR) of 0.49 after adjustment for factors including comorbidities, medications, and glycemic control. Those on SGLT2 inhibitors also had a significantly reduced risk for mortality (adjusted HR=0.49).
These findings, published in Rheumatology, follow earlier research indicating that SGLT2 inhibitors are associated with a lower risk for gout than another class of diabetes drug, glucagon-like peptide-1 receptor agonists.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group